BIOMARIN PHARMACEUTICAL INC 8-K

What Happened

• On March 16, 2026, BioMarin Pharmaceutical Inc. announced it will discontinue dosing and enrollment in its Phase 2 CANOPY trials of VOXZOGO for Turner syndrome, SHOX‑deficiency and Aggrecan (ACAN)‑deficiency. The decision follows several slipped capital femoral epiphysis (SCFE) events reported in two investigator‑sponsored trials (not run by BioMarin).

Key Details

• Date filed: March 16, 2026 (Current Report on Form 8‑K).
• Action: Discontinue dosing and enrollment in Phase 2 VOXZOGO trials for Turner syndrome, SHOX‑deficiency, and ACAN‑deficiency.
• Safety context: SCFE events were observed in two investigator‑sponsored trials; BioMarin states no SCFE cases have been observed in its Phase 2 trials for these conditions or in its achondroplasia program.
• Prior exposure: More than 5,000 infants and children have received VOXZOGO for achondroplasia, covering over 10 years of research and more than 10,000 patient‑years of safety data; no SCFE cases reported in achondroplasia or in BioMarin’s hypochondroplasia trials.
• Ongoing trials: The Phase 2 CANOPY studies in Noonan syndrome and in idiopathic short stature (ISS) patients without ACAN‑deficiency (about 95% of the ISS trial) will continue as planned.
• Disclosure note: BioMarin used its investor relations website for this material disclosure and included standard forward‑looking statement caution.

Why It Matters

• For investors, this is a material clinical development update: discontinuing dosing/enrollment in three Phase 2 indications may delay or limit development and future data readouts for those specific VOXZOGO indications.
• The company emphasizes the SCFE events occurred in investigator‑sponsored trials and were not seen in BioMarin’s own trials or in its large achondroplasia safety record, which may be relevant to safety assessments and regulatory review.
• BioMarin will likely update timelines and next steps as it assesses the events; investors should watch for further clinical and regulatory disclosures.